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BACKGROUND: The increasing demand for anesthetic procedures in the gastrointestinal endoscopy
area has not been followed by a similar increase in the methods to provide and control sedation and
analgesia for these patients. In this study, we evaluated different combinations of propofol and
remifentanil, administered through a target-controlled infusion system, to estimate the optimal
concentrations as well as the best way to control the sedative effects induced by the combinations
of drugs in patients undergoing ultrasonographic endoscopy.
METHODS: One hundred twenty patients undergoing ultrasonographic endoscopy were randomized
to receive, by means of a target-controlled infusion system, a fixed effect-site concentration of either
propofol or remifentanil of 8 different possible concentrations, allowing adjustment of the concen-
trations of the other drug. Predicted effect-site propofol (Cepro) and remifentanil (Ceremi) concentra-
tions, parameters derived from auditory evoked potential, autoregressive auditory evoked potential
index (AAI/2) and electroencephalogram (bispectral index [BIS] and index of consciousness [IoC])
signals, as well as categorical scores of sedation (Ramsay Sedation Scale [RSS] score) in the
presence or absence of nociceptive stimulation, were collected, recorded, and analyzed using an
Adaptive Neuro Fuzzy Inference System. The models described for the relationship between Cepro
and Ceremi versus AAI/2, BIS, and IoC were diagnosed for inaccuracy using median absolute
performance error (MDAPE) and median root mean squared error (MDRMSE), and for bias using
median performance error (MDPE). The models were validated in a prospective group of 68 new
patients receiving different combinations of propofol and remifentanil. The predictive ability (Pk) of
AAI/2, BIS, and IoC with respect to the sedation level, RSS score, was also explored.
RESULTS: Data from 110 patients were analyzed in the training group. The resulting estimated
models had an MDAPE of 32.87, 12.89, and 8.77; an MDRMSE of 17.01, 12.81, and 9.40; and
an MDPE of 1.86, 3.97, and 2.21 for AAI/2, BIS, and IoC, respectively, in the absence of
stimulation and similar values under stimulation. Pk values were 0.82, 0.81, and 0.85 for AAI/2,
BIS, and IoC, respectively. The model predicted the prospective validation data with an MDAPE
of 34.81, 14.78, and 10.25; an MDRMSE of 16.81, 15.91, and 11.81; an MDPE of 8.37,
5.65, and 1.43; and Pk values of 0.81, 0.8, and 0.8 for AAI/2, BIS, and IoC, respectively.
CONCLUSION: A model relating Cepro and Ceremi to AAI/2, BIS, and IoC has been developed and
prospectively validated. Based on these models, the (Cepro, Ceremi) concentration pairs that
provide an RSS score of 4 range from (1.8 gmL1, 1.5 ngmL1) to (2.7 gmL1, 0 ngmL1).
These concentrations are associated with AAI/2 values of 25 to 30, BIS of 71 to 75, and IoC of
72 to 76. The presence of noxious stimulation increases the requirements of Cepro and Ceremi
to achieve the same degree of sedative effects. (Anesth Analg 2011;112:331–9)
The requirements for administration of sedationand/or analgesia for minimally invasive diagnosticand therapeutic procedures have increased enor-
mously. Providing anesthesia for gastrointestinal endos-
copy is a good example of this growing area of anesthetic
activity. Sedation and analgesia increase patient comfort
and provide better working conditions for endoscopists.
Several drugs or drug combinations are currently used
in sedation-analgesia. Propofol is the most frequently used,
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combined or not with remifentanil. Target-controlled infu-
sions (TCIs) allow the administration of IV drugs to achieve
and maintain a certain target concentration in either plasma
or biophase according to pharmacokinetic-pharmacodynamic
(PK-PD) models.1
Although the demand for sedation-analgesia has in-
creased because of patient and endoscopist requirements,
there has not been a proportional increase in establishing
the adequate drug combination or the optimal way to
control sedation. Different systems have been used to
assess the level of patient hypnosis. Besides the observer
evaluation of sedation by means of categorical scores such
as the Ramsay Sedation Scale (RSS) score2 or the Observer’s
Assessment of Alertness/Sedation (OAA/S) score,3 meth-
ods based on the analysis of the spontaneous electroen-
cephalographic (EEG) signal such as the bispectral index
(BIS),4 or based on the analysis of the auditory evoked
potentials (AEPs) such as the autoregressive auditory
evoked potential index (AAI/2),5 have been used for sur-
gical procedures. Most of the studies on sedation recom-
mend target BIS values in the range of 80 to 65 depending
on the depth of sedation (RSS score 3–4 or OAA/S score
3–2). Because patients undergoing endoscopic explorations
are for the most part outpatients, drug effects must be
carefully titrated to warrant a fast hospital discharge after
the procedure is finished. Methods to optimize the control
of sedative and analgesic effects would improve adjusting
drug administration to achieve exactly the level of effect
desired.
Adaptive Neurofuzzy Inference System (ANFIS) is a
fuzzy logic-based modeling approach that establishes the
relationship between variables based on a nonrestricted
mathematical structure, but simply going through the data
with no prior assumption of the mathematical relationship
between variables.6,7 The advantage of using ANFIS is that
it is a data-driven approach that does not assume an
underlying mathematical model governing the relationship
between the anesthetic drugs and the response-effect.
The hypothesis of this project is that available methods
to control hypnosis during surgery could be used to control
the sedative effects induced by different combinations of
propofol and remifentanil, administered by means of a TCI
system, in patients undergoing ultrasonographic endos-
copy (USE). Based on the above, the objectives were to use
the model predictions to define the optimal combination of
propofol and remifentanil to keep patients unconscious,
although arousable by tactile stimulation, and also to define
the recommended ranges of BIS, AAI/2, and the newly
introduced index of consciousness (IoC) monitor associated
with that level of sedation.
METHODS
This was a randomized, observational, nonblinded study.
After receiving approval from the Ethics Committee of
Hospital Clinic de Barcelona and signed informed consent,
120 patients scheduled to undergo USE under sedation-
analgesia were randomized to 1 of 8 different groups
according to the drug combination received. USE was
chosen because it is a relatively long procedure, approxi-
mately 1 hour, with periods of stability of effect and others
when the intensity of endoscopic stimulus is evident,
allowing study of the repercussion of painful stimulus on
the level of sedation.
A second group of 68 patients undergoing the same
endoscopic procedure was also included in the study and
used to prospectively validate the concentration-effect
models. In this group, propofol and remifentanil were not
randomized but administered according to the clinical
judgment of the attending anesthesiologist.
Drug Administration
Using a crisscross design for drug administration, patients
received a combination of propofol and remifentanil in which
1 of the drugs was fixed depending on the group that the
patient was assigned to by the randomization process. The
details of the target concentrations defining the 8 groups are
shown in Table 1. The fixed drug was kept constant through-
out the whole procedure and the other drug, nonfixed, was
allowed to vary according to clinical demands. Crisscross
design warrants the collection of enough data at all possible
drug combinations of propofol and remifentanil.8
Propofol and remifentanil were infused using a TCI
system (FreseniusVial; Chemin de Fer, Be´ziers, France). The
TCI system administered propofol according to the predic-
tions of the PK-PD model described by Schnider et al.9,10
and remifentanil according to the predictions of the PK-PD
model described byMinto et al.11 In both cases, the TCI was
targeting the effect site.
Effect Measurements
After arrival in the USE room, every patient was routinely
monitored, including electrocardiogram, noninvasive arte-
rial blood pressure (ABP), pulse oximetry (Spo2), and
respiratory rate using transcutaneous bioimpedance col-
lected from the electrocardiogram electrodes.
BIS of the EEG was continuously measured using an
A2000 monitor (software version 3.31) (Aspect Medical
Systems, Newton, MA). A 4-electrode sensor was placed on
the foreheads of the patients according to the manufacturer’s
instructions. The AAI/2 derived from AEP signal was
recorded using the AEP monitor/2 (Danmeter, Odense,
Denmark). A 3-electrode montage was used: middle fore-
head (), malar bone (), and left forehead electrode used
as reference. From the same AAI/2 electrodes, the raw EEG
signal was recorded and stored into a flash memory card.
Table 1. Crisscross Design: Target Effect-Site
Concentrations (Ce) for Each Group and Number of
Individuals Analyzed in the Training Set
Target levels of
the drugs
Range of Ce of the
other drug
No. of
individuals
Propofol (g·mL1)
0 1.5–3.5 10
1.5 0.5–3.8 16
2 0.6–2.7 15
3 0.5–2 12
Remifentanil (ng·mL1)
0 1.4–3.8 14
0.5 1.5–4 16
1 0.5–3.8 14
2 1–2.8 13
Patients assigned propofol 0 required remifentanil concentrations ranging
from 1.5 to 3.5 ng·mL1. Similar interpretation for the remaining 7 groups.
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The IoC (Aircraft Medical, formerly Morpheus Medical,
Barcelona, Spain) was calculated off-line from the raw EEG
signal as a composite index combining spectral analysis
and symbolic dynamics as described elsewhere.12,13
The RSS was used as measure of sedation.2 An optimal
level of sedation, based on patients’ preferences and
endoscopists’ demands was defined when the patient
was unconscious, eyes closed, but arousable by tactile
stimulation, which corresponds to an RSS score of 4, a
moderate degree of sedation. The RSS score was evaluated
at random times during the procedure to avoid those
factors correlated with time, which could confound the
results of the RSS measurements.
The presence or absence of the tube inside the upper
digestive tract of the patient was also recorded and consid-
ered as “stimulation” (STIM) when it was present and “no
stimulation” (NO STIM) when absent.
Data Collection
Demographic patient data were collected. Data from the
TCI system including infusion rates, target, plasma, and
effect-site predicted concentrations of propofol (Cepro) and
remifentanil (Ceremi), from the BIS monitor (BIS, electro-
myogram activity), from the A-Line monitor (AAI/2, raw
EEG), and from the hemodynamics monitor (heart rate
[HR], ABP, Spo2, and respiratory rate) were also collected
using the software Rugloop II (Demed, Temse, Belgium).
Data were automatically recorded with a resolution of 1
data point every 5 seconds and stored in the hard drive
of the computer for posterior processing and analysis.
MATLAB™ (MathWorks, Inc., Natick, MA) was used to
write the program that allows processing and synchroniz-
ing the data derived from the different monitors used to
quantify drug effects.
Clinical Management
Patients were asked to lie in the left lateral decubitus
position for at least 5 minutes before drug infusion started.
In case of inadequate sedation after infusion started, hemo-
dynamic depression (HR 45 bpm or mean ABP 60 mm
Hg), respiratory depression (Spo2 94% or respiratory rate
6 breaths per minute), or any other event judged to
endanger the patient or the normal conduct of the explo-
ration by the attending anesthesiologist, clinical actions
were undertaken, including, if necessary, intravascular
volume infusion, atropine or ephedrine administration,
variations in the fixed drug, or discontinuation of drug
administration.
Data Analysis
ANFIS modeling was used to define the interaction of
Cepro and Ceremi with respect to the following effect
measures: (1) AAI/2, (2) BIS, and (3) IoC, in the presence or
absence of noxious stimulation, as defined previously. EEG
and AEP data were used in the modeling process provided
that signal quality was 50%.
ANFIS is a hybrid between a fuzzy logic system and a
neural network. Its background and methodology have
been described elsewhere7 and an application to the prob-
lem of evaluation of depth of anesthesia has also been
published.14 In our case, the ANFIS system as implemented
in MATLAB was fed with 2 inputs: Cepro and Ceremi.
Every input was “fuzzified” into 2 classes where the
membership function was Gaussian. Each input presented
to ANFIS is then assigned a class and a probability of
belonging to that class. In our case, classes were “high
propofol” versus “low propofol” and “high remifentanil”
versus “low remifentanil,” according to the predicted
effect-site concentrations of each drug. The output function,
which was of zero order, defuzzies the data back to crisp
values. This means that any surface shape can result from
the training, not necessarily a sigmoidal-shaped surface.
The resulting surface will be the one that corresponds best
to the relationship between input and output of the model,
in terms of minimizing a least mean square function. In
summary, each model had 2 inputs, Cepro and Ceremi, and
1 output, either AAI/2, BIS, or IoC and the relationship is
described by the surface that optimally describes it.
The number of training epochs chosen was 50 to reduce
the training error. The model was fit to the data by iteratively
minimizing the root mean square errors (RMSEs) using a
backpropagation gradient descent method. ANFIS esti-
mated the parameters of the models that best fit the data for
the combinations of Cepro and Ceremi with respect to the
different measures of sedative effects studied.
Evaluation of Model Performance
To statistically evaluate the performance of the model, the
percentage performance error (PE) defined by Varvel et
al.15 as the difference between the observations and the
predictions of the model divided by the predicted values
was calculated for every data point recorded in each
individual as follows:
PE Obs Pred/Pred
Where Obs means observations and Pred the correspond-
ing value predicted by the model. The median of the PE
(MDPE) and of the absolute values of PE (MDAPE) for
every subject were computed for all patients included in
the study. The median of all the individual MDPEs and
MDAPEs was also calculated and reported as indicator of
bias and inaccuracy, respectively.15
Because the range of the values taken by AAI/2, on one
side, and by BIS and IoC, on the other side, are different for
sedation, it might be worthwhile to consider an alternative
measure of accuracy based on the difference between
observations and predictions instead of normalizing it to
the predicted values. For that purpose, the RMSE is also
computed for each model. The RMSE is defined as:
RMSE 1N Obs Pred2
Where N is the number of observation/prediction pairs.
Similarly to MDPE and MDAPE, the value considered in
this study is the median of the RMSE achieved for each
patient (MDRMSE).
Different hypnotic effect measures were recorded dur-
ing the study. To evaluate which was more accurate in
predicting the level of patient sedation, the ability of the
different effect measures used in predicting the degree of
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sedation, as measured by the RSS, was assessed by calcu-
lating the Pk statistic as described by Smith et al.,
16 which
has been extensively used elsewhere.17 At this step, Cepro
and Ceremi as well as hemodynamic measures (ABP, HR)
were also evaluated as predictors of the RSS values.
Model Validation
The model obtained based on the training group data was
used to predict the values of AAI/2, BIS, and IoC induced
by Cepro and Ceremi in the prospective validation group.
MDAPE, MDRMSE, and MDPE, as well as Pk value, were
also calculated for the studied measures of effect in the
prospective validation group.
Model Application
To estimate the values of the hypnosis monitors associated
with an RSS score of 4, the values of Cepro and Ceremi,
captured from the TCI system, that induced an RSS score of
4 in the individuals of the training group were used as
input to the different models to predict the values of
AAI/2, BIS, and IoC associated with that level of sedation.
RESULTS
Training Group
Data from only 110 patients could be used in the data
analysis process of the training group. Technical problems
(accidental IV line disconnection, transient malfunction of
the data collection system) prevented the collection of
reliable data from the remaining 10 patients. Table 1 shows
the number of individuals included in each group and the
range of predicted concentrations of the drug adjusted to
clinical demands for each fixed drug concentration. Demo-
graphic patient characteristics are shown in Table 2. The
median (range) duration of each exploration was 71 min-
utes (29–216 minutes).
A total of 1304 evaluations of RSS score were performed
in the 110 patients from the training group. The median
number of RSS score evaluations was 11 per patient. A total
of 708 were performed without stimulation, whereas the
remaining 596 were performed under stimulation.
With respect to neurophysiological measures, 51,000
data points were collected (approximately 23,000 without
stimulation and 28,000 with stimulation).
In 90 training group patients, it was possible to maintain
the randomized fixed concentration during the whole pro-
cedure. In the remaining 20, changes were made. The main
reasons for these changes were an inadequate level of
sedation, when the patient was too responsive, and when
anesthesia was too deep for the level required to ad-
equately conduct the procedure.
In the training group, there were 4 apnea events that
required stopping drug infusion and manual ventilation
support. In 3 patients, it was necessary to administer
atropine for bradycardia (2 cases) or ephedrine for hypo-
tension, respectively.
Modeling
The output functionwas of zero order, hence the total number
of parameters in the model was 16. The results of the
modeling process are presented in Figures 1 to 3. Each graph
shows the relationship between Cepro, Ceremi and the differ-
ent effects measured. The distribution of the observations in
the 3-dimensional plot is summarized using cubes whose
volumes are proportional to the number of observations
encountered in each local region of this 3-dimensional space.
For each graph, a fixed volume is assigned to the cube
corresponding to the highest number of observations and the
volume of all the remaining cubes is derived proportionally.
This is intended to optimize the visualization for each plot,
but attention should be given to the fact that 2 cubes of equal
volume from distinct plots do not account for the same
number of observations. With the same aim of facilitating the
Table 2. Demographic Characteristics of the
Patients in Both Groups
Training Validation
Age (y) 61 (19–83) 62 (22–83)
Weight (kg) 67 (41–119) 68 (46–107)
Height (cm) 165.5 (145–192) 164.5 (140–183)
Gender (male/female) 72/38 45/23
Data are median (range).
Figure 1. Model of the relationship between effect-site propofol and effect-site remifentanil with respect to the autoregressive auditory evoked
potential index. The graph on the left shows the relation when there is no noxious stimulation to the patient, and the graph on the right when
there is noxious stimulation. Observations are grouped in cubes whose sizes are proportional to the number of observations. The colored
surface corresponds to the predictions of the model and the intensity of the color relates to the level of effect. Note that the origin of each
graph, the predictions when there is no drug given, is on the lower left corner.
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interpretation of the graphs, each cube is colored according to
the measured effect and orthogonal projections are drawn.
The prediction of the ANFIS model is represented by the
colored surface. In all figures, the graph on the left side shows
the model estimated for the data collected without noxious
stimulation whereas the graph to the right shows the model
estimated when there was noxious stimulation. Figure 1
shows the results for AAI/2, Figure 2 for BIS, and Figure 3 for
IoC. For each measure of effect, 2 models were constructed
depending on the presence or absence of noxious stimulation.
Table 3 summarizes the values of MDAPE, MDRMSE,
and MDPE for every EEG-derived measure of effect stud-
ied under stimulation and without noxious stimulation. For
the training group, AAI/2 presents median values of the
individual MDAPE 30% whereas BIS and IoC values are
approximately 10%. Similar values of MDRMSE are found
for the 3 indexes. Regarding MDPE for the training group,
the median of the individual MDPE is globally well cen-
tered, suggesting very little bias in the individuals of the
training group, except for AAI/2 under stimulation.
Table 4 shows the Pk values calculated for every effect
measure, including Cepro, Ceremi, as well as HR and
systolic ABP, to predict the RSS score.
Prospective Validation Group
A total of 68 patients were included in the prospective
validation group. Demographics of these patients are sum-
marized in Table 2. The predicted effect-site concentrations
Figure 2. Model of the relationship between effect-site propofol and effect-site remifentanil with respect to bispectral index. The graph on the
left shows the relation when there is no noxious stimulation to the patient, and the graph on the right when there is noxious stimulation.
Observations are grouped in cubes whose sizes are proportional to the number of observations. The colored surface corresponds to the
predictions of the model and the intensity of the color relates to the level of effect. Note that the origin of each graph, the predictions when
there is no drug given, is on the lower left corner.
Figure 3. Model of the relationship between effect-site propofol and effect-site remifentanil with respect to index of consciousness. The graph
on the left shows the relation when there is no noxious stimulation to the patient, and the graph on the right when there is noxious stimulation.
Observations are grouped in cubes whose sizes are proportional to the number of observations. The colored surface corresponds to the
predictions of the model and the intensity of the color relates to the level of effect. Note that the origin of each graph, the predictions when
there is no drug given, is on the lower left corner.
Table 3. Indicators of Performance of the Model:
Inaccuracy and Bias
NOSTIM STIM
AAI/2 BIS IoC AAI/2 BIS IoC
Training
group
MDAPE 32.87 12.89 8.77 39.57 12.88 12.43
MDRMSE 17.01 12.18 9.40 15.31 11.19 10.34
MDPE 1.86 3.97 2.21 17.05 2.86 0.49
Validation
group
MDAPE 34.81 14.78 10.25 33.71 15.85 12.85
MDRMSE 16.81 15.91 11.81 12.39 13.25 11.50
MDPE 8.37 5.65 1.43 18.69 5.83 8.16
NOSTIM  absence of noxious stimulation; STIM  presence of noxious
stimulation; AAI/2  autoregressive auditory evoked potential index; BIS 
bispectral index; IoC  index of consciousness; PE  (Obs  Pred)/Pred:
percentage performance error; MDAPE  median of individual median abso-
lute PE, indicator of inaccuracy; MDRMSE  median of individual root mean
squared error, indicator of inaccuracy; MDPE  median of individual median
PE, indicator of bias.
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achieved in this group of patients ranged from 0 to 3.5
gmL1 for propofol and 0 to 2 ngmL1 for remifentanil.
The median (range) duration of the procedure was 63
minutes (24–124 minutes).
Eight hundred twenty evaluations of RSS score were
performed in the 68 patients from the prospective valida-
tion group. The median number of evaluations per patient
was 12. From those 820, 483 were performed with the
patient not being stimulated whereas the remaining 337
were performed while the patient had the endoscopy tube
inside and the exploration was being performed.
With respect to neurophysiological measures, approxi-
mately 25,000 data points were collected (approximately
10,000 without stimulation and 15,000 with stimulation).
Table 3 shows the overall values of MDAPE, MDRMSE,
and MDPE allowing a comparison between training and
validation. As can be seen in the table, the values of
MDAPE and MDRMSE are similar to those calculated in
the training group, suggesting a similar degree of accuracy
of the model to predict the observations from a different set
of patients. The distribution of the individual values of
MDPE suggests an increase in the bias of the model to
prospectively predict the new individuals of the prospec-
tive validation group.
Table 4 shows the Pk values calculated for every effect
measure to predict the RSS score in the validation group. Pk
values were calculated pooling the STIM and NO STIM
data. The values reported suggest good prediction ability
for AAI/2, BIS, and IoC in the prospective validation group
patients.
Model Application
Figure 4 shows the distribution of predicted Cepro and
Ceremi that had an associated measured RSS score of 4 in
the patients of the training group. Those median values of
Cepro and Ceremi were used as input to the model to
estimate the predictions of AAI/2, BIS, and IoC associated
with an RSS score of 4; the results are shown in Figure 5.
Noxious stimulation implies an increase in the target Cepro
and Ceremi to achieve the same level of sedation.
DISCUSSION
This study demonstrates that to achieve and maintain an
RSS score of 4, remifentanil administration reduces the
required propofol predicted concentrations. The models
predict that for those concentrations, the values of BIS,
AAI/2, and IoC are 71 to 75, 25 to 30, and 72 to 76,
respectively. At the concentrations of propofol and
remifentanil used in the study, it has been possible to
evaluate almost all possible combinations of both drugs
and their corresponding sedative effects. The presence of
stimulation required an increase in drug concentration
targets to maintain the same level of effect. IoC, BIS, and
AAI/2 exhibited good performance to control sedation
based on their Pk values.
The values for MDAPE, MDRMSE, and MDPE in the
training group show that the model selected is able to
effectively describe the data recorded without stimulation,
based on good accuracy and almost no bias. The model is
robust in that approximately the same values for MDAPE,
MDRMSE, and MDPE are calculated when it predicts the
observations in the prospective validation group, as can be
seen in Table 3. The AAI/2 presents higher MDAPE values
than BIS and IoC. The similar values of MDRMSE pre-
sented by the 3 indexes show that this larger MDAPE for
AAI/2 is likely attributable to the fact that a given level of
sedation produces higher values for BIS and IoC as com-
pared with AAI/2. For the same reason, AAI/2 tends to
show higher MDPE values. The model for AAI/2, BIS,
and IoC defined under stimulation shows similar accu-
racy and bias.
The behavior of the monitors of the level of sedation can
be assessed by observing their ability to predict the RSS
score as quantified by the Pk statistic. All 3 exhibited a good
predictive ability, both in the training and in the prospec-
tive validation groups. The training group IoC had a Pk
value of 0.85 (AAI/2: 0.82 and BIS: 0.81), whereas in the
Figure 4. Observed effect-site propofol (Cepro) and effect-site
remifentanil (Ceremi) associated to a Ramsay Sedation Scale score
of 4 in the training group. The thick line represents the median value,
the box contains the range of predicted concentrations between the
25th and 75th percentiles, and the whiskers the 5th and 95th
percentiles. This range of concentrations will be fed to the model to
obtain predictions of the expected effect on autoregressive auditory
evoked potential index, bispectral index, and index of consciousness.
Table 4. Pk Comparison: Ability of Each Measure of Effect to Predict the Observed Ramsay Sedation
Scale Score
AAI/2 BIS IoC Cepro Ceremi HR ABP
Training group
Pk (SE) 0.82 (0.01) 0.81 (0.01) 0.85 (0.01) 0.75 (0.01) 0.59 (0.02) 0.63 (0.01) 0.69 (0.02)
Validation group
Pk (SE) 0.81 (0.01) 0.80 (0.01) 0.80 (0.01) 0.66 (0.01) 0.67 (0.01) 0.6 (0.02) 0.64 (0.02)
Data from STIM (presence of noxious stimulation) and NOSTIM (absence of noxious stimulation) are pooled.
SE  standard error of Pk; AAI/2  autoregressive auditory evoked potential index; BIS  bispectral index; IoC  index of consciousness; Cepro  effect-site
propofol; Ceremi  effect-site remifentanil; HR  heart rate; ABP  arterial blood pressure.
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prospective validation, AAI/2 had a Pk of 0.81 (BIS: 0.80
and IoC: 0.80). Such values of Pk are slightly lower than
those reported by other authors, which could be explained
by the fact that our study was performed in real patients
with real noxious stimuli applied under clinical conditions,
which is not as well controlled as a volunteer study. Also,
the present study was performed under non–steady-state
conditions. Hemodynamic parameters had Pk values 0.7
in both groups and Cepro 0.75 in the training group and
0.66 in the prospective validation group.
Struys et al.18 studied the ability of BIS and AAI to predict
sedative responses (OAA/S scale, AAI, and BIS) induced by a
gradually increasing TCI of propofol targeting the biophase,
starting at 1 gmL1 and up to 8 gmL1 under 3 different
concentrations of remifentanil (0, 2, and 4 ngmL1), a differ-
ent design from the “crisscross” used in the present work. The
ability of AAI and BIS to predict OAA/S scores as quantified
by their pooled Pk values were 0.87 and 0.9, significantly
higher values than in our study.
Using Cepro and Ceremi as input to the model, the
expected values for AAI/2, BIS, and IoC corresponding to
RSS score 4 can be estimated and used as objective targets
to predict the desired sedation level without applying any
stimulation to the patient to assess the level of sedation.
The effect of stressful stimulation as in this case, the
introduction of the endoscopy probe through the mouth,
pharynx, and upper digestive tract of the patient, shifts the
shape of the surface upward of all sedative effects studied,
suggesting that increased drug requirements are necessary
to maintain the same level of sedation than without stimu-
lation. It can be better assessed by looking at Figure 5 where
for AAI/2, BIS, and IoC, an influence of noxious stimula-
tion can be seen. This effect is more evident in the case of
AAI/2, where a value of 25 to 30 can be achieved with
Cepro 3.8 to 2.9 gmL
1 whereas Ceremi increases from 0.7
to 2 ngmL1. When there is noxious stimulation, Cepro
shifts from 4 to 3.2 gmL1, whereas Ceremi increases
from 1.6 to 2.5 ngmL1. Although present, differences are
not so obvious for BIS and IoC.
Nieuwenhuijs et al.19 have studied the interaction between
propofol and remifentanil with respect to BIS. They con-
cluded that for propofol concentrations up to 2 g mL1
combined with remifentanil concentrations ranging from 0 to
2 ng mL1, both lower than in our study, there is no synergy
with respect to BIS as a measure of effect. In the present work,
no formal estimation of synergy was attempted, although the
bowing shape of the surfaces relating concentrations and the
different effects suggest that there might be a positive inter-
action. Bouillon et al.20 also studied the interaction between
propofol and remifentanil with respect to hypnotic responses
such as absence of response to shaking and shouting, BIS, and
approximate entropy of the EEG. They concluded that the
addition of remifentanil decreases the concentrations of
propofol required, whereas remifentanil alone, only if given at
very high concentrations and beyond those used clinically,
might induce any sign of sedation. Our study differs in that
our patients underwent real exploration with painful stimuli
that could be intense at some points, unlike a well-controlled
volunteer study.
Kazama et al.21 estimated a propofol 50% concentration
value for loss of consciousness in patients undergoing
gastroscopy ranging from 2.23 to 1.40 g mL1 depending
on the age of the patients; the younger, the more propofol
required. These values are consistent with our estimation
for RSS score 4, which associates unconsciousness to toler-
ate insertion of the gastroscope.
A close observation of model graphs shows that when
remifentanil is given alone or administered with concentra-
tions of propofol1.4 g mL1, there is a tendency to predict
an increase of the values of the indicators calculated from the
EEG effects. A plausible explanation could be the presence of
electromyographic artifact caused by a relatively small contri-
bution of the sedative component of propofol during intro-
duction of the tube. Another explanation is based on the
muscular rigidity associated with the use of powerful opioids
such as remifentanil. Although rigidity was not clinically
observed in any of the patients studied, remifentanil might
increase muscular tone to the point that it might alter the EEG
Figure 5. Model effect predictions for the
autoregressive auditory evoked potential
index (AAI/2), bispectral index (BIS), and
index of consciousness (IoC) effect in-
duced by the median effect-site propofol
(Cepro) and effect-site remifentanil (Ceremi)
associated with a Ramsay Sedation Scale
score of 4. Each graph shows the plots of
the isobologram for the same level of hyp-
notic effect in the absence (continuous
line, NOSTIM) and presence (dashed line,
STIM) of noxious stimulation.
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waves. It must be kept in mind that logically no neuromus-
cular blocking drug was used because it was mandatory that
all patients breathe by themselves. In most studies using the
EEG as a surrogate measure of opioid drug effect, the patients
or volunteers were administered low concentrations of neu-
romuscular blocking drug to avoid rigidity and artifacts on
the EEG recording.
This work uses ANFIS, a fuzzy reasoning-based method
of data analysis. Other authors have used a similar ap-
proach based on fuzzy logic principles to analyze complex
data from clinical studies.22,23 The ANFIS approach allows
the implementation of very complex processes, where a
simple mathematical model cannot be obtained. Fuzzy
logic has been successfully applied to highly nonlinear
systems, where it is observed to greatly simplify the
modeling process. The power of fuzzy logic is to perform
reasonable and meaningful operations on concepts that
cannot be easily codified using a classical mathematical
approach. Such modification allows for a much more
flexible and widespread use of reliable and consistent logic
in a variety of applications. The most common use of fuzzy
logic lies in the field of control systems, although the theory
seems to have serious potential in the different fields of
artificial intelligence. It can be used as a preliminary approach
before conducting a more sophisticated pharmacologic anal-
ysis such as a population approach using mixed effects
modeling techniques. Zhang and Roy14 have used an ANFIS
approach to extract from the EEG parameters that allow
discrimination between awake and asleep states in anesthe-
tized dogs. To make our results more solid, we have at-
tempted to prospectively validate the ANFIS model in a new
set of data, obtaining similar results. This means that the
model could be used safely to predict the effect of propofol
and remifentanil in this kind of procedure and patient.
To conclude, we have used an ANFIS modeling approach
with prospective validation to study the relationship be-
tween propofol and remifentanil predicted concentrations
and sedative effects in patients undergoing USE. Optimal
sedation can be achieved with a target propofol biophase
concentration of 2.8 to 1.8 g mL1 with remifentanil
increasing from 0 to 1.5 ng mL1. The IoC value associated
with such concentrations is 72 to 76, similar to BIS 71 to 75,
whereas the interval for AAI/2 is 25 to 30. The presence of
stimulation requires an increase in the target concentration
of propofol and remifentanil to maintain patients at the
same level of sedation.
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